home

conference

scai

Society for Cardiovascular Angiography and Interventions

Articles

Data from an interim analysis of the DIPRA trial suggest distal radial artery access for cardiac catheterization and resulted in no significant differences in hand function compared to proximal radial artery access. 

DIPRA: Distal Radial Access Safe, No Negative Impact on Hand Function vs Proximal Radial Access

Long-term data from the SAFE-PAD trial at SCAI 2022 underlines the noninferiority of paclitaxel-coated devices versus non-drug-coat devices for use in patients with peripheral artery disease.

SAFE-PAD: No Difference in Mortality with Paclitaxel-Coated Devices Up to 6 Years Out

An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.

Clopidogrel Tops Aspirin for Long-Term Antiplatelet Therapy After PCI in High-Risk Patients

Chair of the SCAI's writing group for their 2022 guidelines on management of patent foramen ovale, Dr. Clifford Kavinsky, sits down with Practical Cardiology to take part in a Q&A on the guideline's recommendations and the writing process for the SCAI's first PFO guidance. 

Q&A on SCAI's 2022 PFO Guidelines, with Clifford Kavinsky, MD, PhD

Patrick Campbell is the assistant managing editor of Endocrinology Network, as well as its sister publications Practical Cardiology and Rheumatology Network. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Results of 1-year follow-up from the Harmony TPV Clinical trial provide insight into the safety and efficacy of the recently approved Harmony TPV system in patients with congenital heart disease and severe pulmonary regurgitation. 

Follow-up Results for Harmony TPV System Demonstrate Efficacy at 1-Year 

An analysis of data from NYU Langone provides perspective into the rapid decline of emergency department presentations for acute myocardial infarction that occurred during the peak of the COVID-19 pandemic. 

Presentations for Acute MIs Dropped Drastically During Peak of COVID-19 Pandemic

An analysis comparing a national registry against ISCHEMIA enrollment criteria suggests trial eligibility represents less than 2% of all patients undergoing PCI and less than a third of patients undergoing PCI with stable ischemic heart disease.

SCAI 2021: ISCHEMIA Represents a Fraction of Patients with SIHD Undergoing PCI

An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population. 